LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Chronic Granulomatous Disease; fundamental stages in our understanding of CGD.

    Assari, Tracy

    Medical immunology (London, England)

    2006  Volume 5, Page(s) 4

    Abstract: It has been 50 years since chronic granulomatous disease was first reported as a disease which fatally affected the ability of children to survive infections. Various milestone discoveries from the insufficient ability of patients' leucocytes to destroy ... ...

    Abstract It has been 50 years since chronic granulomatous disease was first reported as a disease which fatally affected the ability of children to survive infections. Various milestone discoveries from the insufficient ability of patients' leucocytes to destroy microbial particles to the underlying genetic predispositions through which the disease is inherited have had important consequences. Longterm antibiotic prophylaxis has helped to fight infections associated with chronic granulomatous disease while the steady progress in bone marrow transplantation and the prospect of gene therapy are hailed as long awaited permanent treatment options. This review unearths the important findings by scientists that have led to our current understanding of the disease.
    Language English
    Publishing date 2006-09-21
    Publishing country England
    Document type Journal Article
    ISSN 1476-9433
    ISSN (online) 1476-9433
    DOI 10.1186/1476-9433-5-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom.

    Török, M Estée / Underwood, Benjamin R / Toshner, Mark / Waddington, Claire / Sidhom, Emad / Sharrocks, Katherine / Bousfield, Rachel / Summers, Charlotte / Saunders, Caroline / McIntyre, Zoe / Morris, Helen / Piper, Jo / Calderon, Gloria / Dennis, Sarah / Assari, Tracy / de Rotrou, Anita Marguerie / Shaw, Ashley / Bradley, John / O'Brien, John /
    Rintoul, Robert C / Smith, Ian / Bullmore, Ed / Chatterjee, Krishna

    Clinical trials (London, England)

    2021  Volume 18, Issue 5, Page(s) 615–621

    Abstract: The COVID-19 pandemic has resulted in unprecedented challenges for healthcare systems worldwide. It has also stimulated research in a wide range of areas including rapid diagnostics, novel therapeutics, use of technology to track patients and vaccine ... ...

    Abstract The COVID-19 pandemic has resulted in unprecedented challenges for healthcare systems worldwide. It has also stimulated research in a wide range of areas including rapid diagnostics, novel therapeutics, use of technology to track patients and vaccine development. Here, we describe our experience of rapidly setting up and delivering a novel COVID-19 vaccine trial, using clinical and research staff and facilities in three National Health Service Trusts in Cambridgeshire, United Kingdom. We encountered and overcame a number of challenges including differences in organisational structures, research facilities available, staff experience and skills, information technology and communications infrastructure, and research training and assessment procedures. We overcame these by setting up a project team that included key members from all three organisations that met at least daily by teleconference. This group together worked to identify the best practices and procedures and to harmonise and cascade these to the wider trial team. This enabled us to set up the trial within 25 days and to recruit and vaccinate the participants within a further 23 days. The lessons learned from our experiences could be used to inform the conduct of clinical trials during a future infectious disease pandemic or public health emergency.
    MeSH term(s) COVID-19/prevention & control ; COVID-19 Vaccines/therapeutic use ; Clinical Trials as Topic/organization & administration ; Clinical Trials as Topic/standards ; Humans ; Pandemics/prevention & control ; State Medicine ; United Kingdom/epidemiology
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2021-06-22
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2138796-5
    ISSN 1740-7753 ; 1740-7745
    ISSN (online) 1740-7753
    ISSN 1740-7745
    DOI 10.1177/17407745211024764
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5831: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Regulation of alpha(1)-adrenoceptor-linked phosphoinositide metabolism in cultured glia: involvement of protein phosphatases and kinases.

    Assari, Tracy / Cox, Sarah / Munday, Michael R / Pearce, Brian

    Cellular signalling

    2003  Volume 15, Issue 4, Page(s) 403–412

    Abstract: Noradrenaline-stimulated phosphoinositide breakdown in cultured glia was found to be mediated by alpha(1A)-adrenoceptors. The alpha(1A)-selective agonist A61603 was as effective as noradrenaline in eliciting 3H-inositol phosphate (IP) accumulation but ... ...

    Abstract Noradrenaline-stimulated phosphoinositide breakdown in cultured glia was found to be mediated by alpha(1A)-adrenoceptors. The alpha(1A)-selective agonist A61603 was as effective as noradrenaline in eliciting 3H-inositol phosphate (IP) accumulation but was approximately 50-fold more potent. In addition, the use of selective antagonists revealed a clear rank order of potency in the ability of these drugs to reverse the effect of noradrenaline on phosphoinositide breakdown: RS17053 (alpha(1A)-selective) >>AH11110A (alpha(1B)-selective)>BMY7378 (alpha(1D)-selective). Pre-treatment of cultured glia with the protein phosphatase inhibitor okadaic acid resulted in a concentration- and time-dependent reduction in noradrenaline-evoked 3H-IP accumulation. This effect was mimicked by, but was not additive with, a phorbol ester, was reversed by protein kinase C (PKC) inhibitors and was not evident in cells which had been PKC depleted. The ability of cell extracts to dephosphorylate radiolabelled glycogen phosphorylase revealed the presence of the phosphatases PP1 and PP2A in almost equal abundance. Okadaic acid pre-treatment of intact cultures elicited a marked reduction in total phosphatase activity, particularly that mediated by PP2A. We also determined the effect of okadaic acid pre-treatment on PKC and cyclic AMP-dependent protein kinase (PKA) activities in these cells. PKC and PKA activities in cell extracts were assessed by determining the incorporation of 32P into histone and kemptide, respectively. Okadaic acid elicited increases in both Ca(2+)-dependent and Ca(2+)-independent PKC activity; in addition, increases in both initial and total PKA activities were also recorded. The effect of okadaic acid on noradrenaline-stimulated 3H-IP accumulation were not, however, mimicked by either forskolin or 8-bromo-cyclic AMP, suggesting that this event is not regulated by PKA. Our data point to roles for both PKC and PP2A in the regulation of alpha(1A)-adrenoceptor-linked phosphoinositide metabolism in cultured cortical glia.
    MeSH term(s) Adrenergic alpha-Agonists/pharmacology ; Animals ; Cells, Cultured ; Inositol Phosphates/metabolism ; Neuroglia/enzymology ; Neuroglia/metabolism ; Norepinephrine/pharmacology ; Okadaic Acid/pharmacology ; Phosphoprotein Phosphatases/antagonists & inhibitors ; Phosphoprotein Phosphatases/physiology ; Protein Kinase C/antagonists & inhibitors ; Protein Kinase C/physiology ; Rats ; Receptors, Adrenergic, alpha-1/metabolism
    Chemical Substances Adrenergic alpha-Agonists ; Inositol Phosphates ; Receptors, Adrenergic, alpha-1 ; Okadaic Acid (1W21G5Q4N2) ; Protein Kinase C (EC 2.7.11.13) ; Phosphoprotein Phosphatases (EC 3.1.3.16) ; Norepinephrine (X4W3ENH1CV)
    Language English
    Publishing date 2003-01-22
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1002702-6
    ISSN 0898-6568
    ISSN 0898-6568
    DOI 10.1016/s0898-6568(02)00114-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2579: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top